AzTrials
AzTrials

Early PsychosisNCT06032182

PSYCHE Cognitive Remediation & Social Recovery Study

A study testing CRESTR Intervention in people with Early Psychosis, run by National University of Ireland, Galway, Ireland at 5 sites in Ireland.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study is a pilot feasibility study embedded in the Early Intervention in Psychosis (EIP) services in Ireland. It explores the feasibility and acceptability of a combined cognitive remediation training and social recovery therapy intervention. Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Early Psychosis
What is being tested?
CRESTR Intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
5 sitesIreland
Study dates
1 Mar 2023to Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Aged between 18 and 60 years of age
  • Within the first 5 years of a diagnosed psychotic disorder
  • Community based and clinically stable
  • Ability to give informed consent

Who cannot join

  • History of organic impairment
  • IQ< 70
  • History of head injury with loss of consciousness > 5-minute duration

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

Ireland5 sites, 5 recruiting
  • HSE Early Intervention in Psychosis Service, Cork

    Cork

    Dr Karen O'Connor, 0035321 4233164, karen.oconnor3@hse.ie

    Recruiting
  • DETECT Early Intervention in Psychosis Service

    Dublin

    Mary Clarke, Prof.

    Recruiting
  • Adult Mental Health Service, University Hospital Galway

    Galway

    Dr Brian Hallahan, 0035391524222 ext. 4162, brian.hallahan@universityofgalway.ie

    Recruiting
  • HSE Early Intervention in Psychosis Service, Meath

    Navan

    Dr Marie Whitty, marie.whitty@hse.ie

    Recruiting
  • HSE Early Intervention in Psychosis Service, Sligo

    Sligo

    Dr Donagh O'Neil, donagh.oneill@hse.ie

    Recruiting

Other trials in Ireland

About this study

Official title: PSYCHE Cognitive Remediation & Social Recovery in Early Psychosis Study

This study is a pilot feasibility study embedded in the Early Intervention in Psychosis (EIP) services in Ireland. It explores the feasibility and acceptability of a combined cognitive remediation training and social recovery therapy intervention.

Read the detailed description

The Cognitive Remediation and Social Recovery in Early Psychosis (CRESTR) study is a feasibility study recruiting participants from the Health Service Executive Early Intervention in Psychosis (EIP) services in Sligo, Meath and Cork and the Adult Mental Heath Service in Galway. This study explores the feasibility and acceptability of a novel, 15-week multicomponent psychosocial intervention which combines cognitive remediation training (CRT) and social recovery therapy (SRT). Primary and secondary outcome measures are described later in this registration. The intervention components include:

Component 1: The CRT programme used in this study is the Computerised Interactive Remediation of Cognition- Training for Schizophrenia (CIRCuiTS). CIRCuiTS is a web-based CRT programme which targets metacognition, specifically strategy use, in addition to massed practice of cognitive functions (attention, memory and executive functioning). Collaborative goal setting related to real-world tasks are integral to the programme with the programme tasks and exercises increasing in difficulty in response to the participant's performance and progress. This will be the primary focus of 1:1 therapy for the first 7 weeks with remote practice sessions occurring between therapy visits. After 7 weeks remote practice will continue and the focus of in-person therapy sessions will bridge to social recovery therapy as detailed below.

Component 2: Social recovery therapy (SRT) focuses on addressing barriers to individuals interacting in their social environment e.g., social anxiety. It is informed by cognitive behavioural theory and addresses individual goals. SRT follows an established protocol. In summary, this consists of therapy delivered in three stages. Stage one will include engagement and formulation with the purpose of identifying a problem list and establishing a therapeutic relationship. Stage two will include preparing for new activities with identification of pathways to activity and collaboration with community stakeholders. Stage three will include engagement in new activities using behavioural experiments to promote social activity. This is the primary focus of in-person therapy sessions from week 8 to 15 alongside remote practice of the CRT programme.

Conditions
Early Psychosis
Being tested
CRESTR Intervention, CRESTR Control
Keywords
Recovery, Cognitive remediation training, Cognitive behavioural therapy, Psychosis
Medical subject headings
Psychotic Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CRESTR InterventionBehavioural

    15 1-hour sessions of CRT + SRT

  • CRESTR ControlBehavioural

    15 1-hour sessions of SRT alone

Study groups in NCT06032182
Study groupRoleWhat they receive
InterventionExperimental15 sessions of the combined cognitive remediation training and social recovery therapy intervention.
Receives: Behavioral: CRESTR Intervention
ControlActive comparator15 sessions of social recovery therapy alone.
Receives: Behavioral: CRESTR Control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Social and Occupational Functioning Assessment Scale

    Social and Occupational Functional Assessment Scale (Rybarczyk, 2011) is a global rating of current functioning ranging from 0 to 100, with lower scores representing lower functioning.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

Secondary outcomes (17)
  1. The Reading the Mind in the Eyes Task

    The Reading the mind in the eyes task is a theory of mind task that measures the capacity to understand mental states of others from expressions in the eye region of the face. Participants view 36 photos and choose the most accurate descriptor word from four choices for the thought/feeling that was portrayed. Scores range from 0 to 36 with higher scores indicating better theory of mind ability.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  2. Emotion Recognition Task

    The Emotion Recognition Task from the Cambridge Neuropsychological Test Automated Battery (Cambridge Cognition Ltd.)

    Computer-morphed images derived from the facial features of real individuals, each showing a specific emotion, are displayed on the screen, one at a time. Each face is displayed for 200ms and then immediately covered up to prevent residual processing of the image. The participant must select which emotion the face displayed from 6 options (sadness, happiness, fear, anger, disgust or surprise).

    The outcome measures for ERT will include number correct, which can be looked at either across individual emotions or across all emotions at once. Higher scores indicate superior emotion recognition ability.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  3. The Bell Lysaker Emotion Recognition Task

    The Bell Lysaker Emotion Recognition Task measures recognition of seven emotional states: happiness, sadness, fear, disgust, surprise, anger, or no emotion. Participants identified the emotion shown in 21 videos of a male actor providing dynamic facial, vocal-tonal, and upper-body movement cues. Performance is indexed as the total number of correctly identified emotions (ranging from 0 to 21 i.e. a higher score represents superior emotion recognition ability.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  4. Test of Premorbid Functioning

    Test of Premorbid Functioning estimates an individual's pre-morbid cognitive and memory functioning. A revised and updated version of the Wechsler Test of Adult Reading™, TOPF helps predict pre-injury IQ and memory abilities. Total score is derived from the number of correct items, ranges from 0-70 with a higher score indicating superior ability.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  5. The matrix reasoning subtest from the Wechsler Adult Scale of Intelligence 3rd edition (WAIS-III)

    The matrix reasoning subtest from the Wechsler Adult Scale of Intelligence 3rd edition (WAIS-III) (Wechsler, 1997) is a brief, reliable measure of cognitive ability for use in clinical, educational and research settings. Matrix reasoning subtest scores range from 0 - 26 with higher scores reflecting better perceptual organization. Once raw scores are derived they are converted to scaled scores adjusted for age.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  6. Letter Number Sequencing Task

    The letter-number sequencing task from the Wechsler Memory scale 3rd edition WMS-III assesses working memory. Scores range from 0-21. Higher scores on the WMS-III subtests indicate better memory function. Raw scores are converted to scaled scores adjusted for age.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  7. Metacognitive Awareness Scale, Domain Specific

    Meta-Cognitive Awareness Scale - Domain Specific encourages reflection of task strategy processes. This domain-specific scale was first constructed to measure participants' awareness of their own metacognition linked to Raven's Progressive Matrices (SPM). Following discriminatory index and Exploratory Factor Analysis, a 15-item scale was derived. Exploratory Factor Analysis showed five factors: Awareness of Engagement in Self-Monitoring, Awareness of Own Ability, Awareness of Responding Speed/Time, Awareness of Alternative Solutions and Awareness of Requisite Problem-Solving Resources. The total score is the sum of the 15-itm scale with higher scores indicating superior metacognitive awareness.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  8. The Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms.

    The Scale for the Assessment of Positive Symptoms measures positive symptoms on a 24 item scale, this includes 19 negative symptom item ratings, and 5 global factor ratings. Each item is scored on a six point scale from 0-5. The composite total is the sum of the nineteen item ratings. The SANS global total is the sum of the five global ratings. The higher the score the more symptomology or severity of symptoms.

    The Scale for the Assessment of Negative Symptoms measures negative symptoms on a 25 item, 6-point scale from 0-5. Items are listed under the five domains of affective blunting, alogia, avolition/apathy, anhedonia/asociality, and attention. Total (Composite) score is calculated as the sum of SANS items 1-7, 9-12, 14-16, 18-21, and 23-24, while SANS (Global) Summary score was calculated as the sum of SANS items 8, 13, 17, 22, and 25. The higher the score the more symptomology or severity of symptoms.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  9. The Patient Health Questionnaire-9

    The Patient Health Questionnaire-9 is a brief tool used to diagnose and measure severity of depression. It is adapted from the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Scores range from 0 to 27 with higher scores indicating more severe depression.

    A total score of 0-4 points equals "normal" or minimal depression. Scoring between 5-9 points indicates mild depression, 10-14 points indicates moderate depression, 15-19 points indicates moderately severe depression, and 20 or more points indicates severe depression.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  10. The Generalised Anxiety Disorder Assessment-7

    The Generalised Anxiety Disorder Assessment is a seven-item instrument that is used to measure or assess the severity of generalised anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Total scores range from 0 to 21with higher scores indicating a higher level of anxiety. Clinical categorisations of anxiety levels are: 0-4 (none), 5-9 (mild), 10-14 (moderate), and 15-21 (severe).

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  11. Drug Use Disorders Identification Test

    The Drug Use Disorders Identification Test is an 11-item self-administered screening instrument for drug-related problems, giving information on the level of drug intake and selected criteria for substance abuse/harmful use and dependence according to the ICD-10 and DSM-4 diagnostic systems. The minimum total score possible is 0, and the maximum total score possible is 44 (i.e. total score range: 0-44). Higher scores reflect higher drug dependence

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  12. Alcohol Use Disorders Identification Test

    The Alcohol Use Disorders Identification Test is a 10-item screening tool developed by the World Health Organization (WHO) to assess alcohol consumption, drinking behaviors, and alcohol-related problems. The range of possible scores is from 0 to 40 where 0 indicates an abstainer who has never had any problems from alcohol. A score of 1 to 7 suggests low-risk consumption according to World Health Organization (WHO) guidelines. Scores from 8 to 14 suggest hazardous or harmful alcohol consumption and a score of 15 or more indicates the likelihood of alcohol dependence (moderate-severe alcohol use disorder).

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  13. EQ-ED-EL Health Questionnaire

    The EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each level is rated on scale that describes the degree of problems in that area (i.e. I have no problems walking about, slight problems, moderate problems, severe problems, or unable to walk). This tool also has an overall health scale where the rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  14. Global Functioning Scale

    The Global Functioning Scale: Role: measures performance and amount of support needed in one's specific role (ie, school, work). Social: measures quantity and quality of peer relationships, level of peer conflict, age-appropriate intimate relationships, and involvement with family members. Scale: 1-10, higher scores indicate better functioning.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  15. MIRECC Global Assessment of Function

    The MIRECC Global Assessment of Function measures occupational functioning, social functioning, and symptom severity on 3 subscales. 3 subscales scored from 0 to 100, with higher scores indicating better functioning.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  16. Global Assessment of Function

    The Global Assessment of Function scale is a 100-point single-item scale designed to measure the global severity of psychiatric illness on the basis of symptom, social, and occupational functioning combined. The scale is divided into 10 anchor intervals, with descriptions and examples of symptoms and of social and occupational functioning. Higher scores indicate better functioning.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

  17. Time Use Survey

    The Time Use Survey is a semi-structured interview that enquires about time spent over the past month on work, education, voluntary work, leisure, sports, housework or chores, and child care. Time spent on each of the activities is calculated in terms of the average number of hours per week. The activities are summed to create two scores: constructive economic activity (work, education, voluntary work, housework or chores, and child care) and structured activity (constructive economic activity plus leisure and sports activities). Less than 45 hours of structured activity per week is considered a threshold for being at risk of social disability, less than 30 hours per week is threshold for social disability and indicative of poor social functioning, and less than 15 hours per week is considered to reflect serious social disability.

    Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Sep 2023
  2. Study start1 Mar 2023
  3. Primary completionJun 2025 (estimated)
  4. Study completionDec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06032182
Sponsor's protocol ID
NUIRELAND2
Status last verified
Mar 2024
First submitted
30 Aug 2023
Last updated
22 Mar 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The full protocol in addition to datasets and statistical code generated during the current study will be available from the corresponding author on reasonable request.

Questions about this trial

What is this clinical trial studying?

A study testing CRESTR Intervention in people with Early Psychosis, run by National University of Ireland, Galway, Ireland at 5 sites in Ireland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Prof. Gary Donohoe (0035391495122, gary.donohoe@universityofgalway.ie), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Social and Occupational Functioning Assessment Scale (time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in